10-Q Filing

TEVA PHARMACEUTICAL INDUSTRIES LTD CIK: 818686 Q1 2023

Filing Information

Form Type	10-Q
Accession Number	`0001193125-23-140697`
Period End Date	20230331
Filing Date	20230510
Fiscal Year	2023
Fiscal Period	Q1
XBRL Instance	d464631d10q_htm.xml

Filing Contents

This filing contains the following financial statements:

Balance Sheet 87 Income Statement 44 Cash Flow Statement 63 Stockholders Equity 15 Comprehensive Income 16

Balance Sheet 87 line items

Line Item	Tag	Value	Unit	Period
Allowance for credit losses	`AllowanceForDoubtfulAccountsReceivableCurrent`	$88.00M	USD	Point-in-time
Allowance for credit losses	`AllowanceForDoubtfulAccountsReceivableCurrent`	$91.00M	USD	Point-in-time
Common stock, par or stated value per share	`CommonStockParOrStatedValuePerShare`	0.10	ILS	Point-in-time
Common stock, par or stated value per share	`CommonStockParOrStatedValuePerShare`	0.10	ILS	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$2.80B	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$2.14B	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$2.17B	USD	Point-in-time
Ordinary shares, authorized	`CommonStockSharesAuthorized`	2.50B	shares	Point-in-time
Ordinary shares, authorized	`CommonStockSharesAuthorized`	2.50B	shares	Point-in-time
Accounts receivables, net of allowance for credit losses of $88 million and $91 million as of March 31, 2023 and December 31, 2022	`AccountsReceivableNetCurrent`	$3.70B	USD	Point-in-time
Ordinary shares, issued	`CommonStockSharesIssued`	1.22B	shares	Point-in-time
Accounts receivables, net of allowance for credit losses of $88 million and $91 million as of March 31, 2023 and December 31, 2022	`AccountsReceivableNetCurrent`	$3.44B	USD	Point-in-time
Ordinary shares, issued	`CommonStockSharesIssued`	1.23B	shares	Point-in-time
Treasury shares	`TreasuryStockShares`	106.00M	shares	Point-in-time
Inventories	`InventoryNet`	$3.83B	USD	Point-in-time
Inventories	`InventoryNet`	$4.12B	USD	Point-in-time
Treasury shares	`TreasuryStockShares`	106.00M	shares	Point-in-time
Prepaid expenses	`PrepaidExpenseCurrent`	$1.25B	USD	Point-in-time
Prepaid expenses	`PrepaidExpenseCurrent`	$1.16B	USD	Point-in-time
Other current assets	`OtherAssetsCurrent`	$542.00M	USD	Point-in-time
Other current assets	`OtherAssetsCurrent`	$549.00M	USD	Point-in-time
Assets held for sale	`AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent`	$10.00M	USD	Point-in-time
Assets held for sale	`AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent`	$10.00M	USD	Point-in-time
Total current assets	`AssetsCurrent`	$11.50B	USD	Point-in-time
Total current assets	`AssetsCurrent`	$12.05B	USD	Point-in-time
Deferred income taxes	`DeferredIncomeTaxAssetsNet`	$1.57B	USD	Point-in-time
Deferred income taxes	`DeferredIncomeTaxAssetsNet`	$1.45B	USD	Point-in-time
Other non-current assets	`OtherAssetsNoncurrent`	$450.00M	USD	Point-in-time
Other non-current assets	`OtherAssetsNoncurrent`	$441.00M	USD	Point-in-time
Property, plant and equipment, net	`PropertyPlantAndEquipmentNet`	$5.75B	USD	Point-in-time
Property, plant and equipment, net	`PropertyPlantAndEquipmentNet`	$5.74B	USD	Point-in-time
Operating lease right-of-use assets	`OperatingLeaseRightOfUseAsset`	$419.00M	USD	Point-in-time
Operating lease right-of-use assets	`OperatingLeaseRightOfUseAsset`	$420.00M	USD	Point-in-time
Identifiable intangible assets, net	`FiniteLivedIntangibleAssetsNet`	$6.27B	USD	Point-in-time
Identifiable intangible assets, net	`FiniteLivedIntangibleAssetsNet`	$5.96B	USD	Point-in-time
Goodwill	`Goodwill`	$17.63B	USD	Point-in-time
Goodwill	`Goodwill`	$17.80B	USD	Point-in-time
Total assets	`Assets`	$43.46B	USD	Point-in-time
Total assets	`Assets`	$44.01B	USD	Point-in-time
Short-term debt	`DebtCurrent`	$1.02B	USD	Point-in-time
Short-term debt	`DebtCurrent`	$2.11B	USD	Point-in-time
Sales reserves and allowances	`SalesReservesAndAllowances`	$3.31B	USD	Point-in-time
Sales reserves and allowances	`SalesReservesAndAllowances`	$3.75B	USD	Point-in-time
Accounts payables	`AccountsPayableTradeCurrent`	$1.89B	USD	Point-in-time
Accounts payables	`AccountsPayableTradeCurrent`	$2.38B	USD	Point-in-time
Employee-related obligations	`EmployeeRelatedLiabilitiesCurrent`	$432.00M	USD	Point-in-time
Employee-related obligations	`EmployeeRelatedLiabilitiesCurrent`	$566.00M	USD	Point-in-time
Accrued expenses	`AccruedExpenses`	$2.27B	USD	Point-in-time
Accrued expenses	`AccruedExpenses`	$2.15B	USD	Point-in-time
Other current liabilities	`OtherLiabilitiesCurrent`	$1.00B	USD	Point-in-time
Other current liabilities	`OtherLiabilitiesCurrent`	$1.00B	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$10.41B	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$11.47B	USD	Point-in-time
Deferred income taxes	`DeferredTaxAndOtherLiabilitiesNoncurrent`	$550.00M	USD	Point-in-time
Deferred income taxes	`DeferredTaxAndOtherLiabilitiesNoncurrent`	$548.00M	USD	Point-in-time
Other taxes and long-term liabilities	`OtherLiabilitiesNoncurrent`	$3.87B	USD	Point-in-time
Other taxes and long-term liabilities	`OtherLiabilitiesNoncurrent`	$3.85B	USD	Point-in-time
Senior notes and loans	`LongTermNotesAndLoans`	$19.10B	USD	Point-in-time
Senior notes and loans	`LongTermNotesAndLoans`	$19.67B	USD	Point-in-time
Operating lease liabilities	`OperatingLeaseLiabilityNoncurrent`	$349.00M	USD	Point-in-time
Operating lease liabilities	`OperatingLeaseLiabilityNoncurrent`	$345.00M	USD	Point-in-time
Total long-term liabilities	`LiabilitiesNoncurrent`	$23.85B	USD	Point-in-time
Total long-term liabilities	`LiabilitiesNoncurrent`	$24.43B	USD	Point-in-time
Commitments and contingencies, see note 10	`CommitmentsAndContingencies`	-	USD	Point-in-time
Commitments and contingencies, see note 10	`CommitmentsAndContingencies`	-	USD	Point-in-time
Total liabilities	`Liabilities`	$35.31B	USD	Point-in-time
Total liabilities	`Liabilities`	$34.84B	USD	Point-in-time
Ordinary shares of NIS 0.10 par value per share; March 31, 2023 and December 31, 2022: authorized 2,495 million shares; issued 1,226 million shares and 1,217 million shares, respectively	`CommonStockValue`	$57.00M	USD	Point-in-time
Ordinary shares of NIS 0.10 par value per share; March 31, 2023 and December 31, 2022: authorized 2,495 million shares; issued 1,226 million shares and 1,217 million shares, respectively	`CommonStockValue`	$57.00M	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapital`	$27.69B	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapital`	$27.72B	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-12.88B	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-13.09B	USD	Point-in-time
Accumulated other comprehensive loss	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	$-2.70B	USD	Point-in-time
Accumulated other comprehensive loss	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	$-2.84B	USD	Point-in-time
Treasury shares as of March 31, 2023 and December 31, 2022: 106 million ordinary shares	`TreasuryStockValue`	$4.13B	USD	Point-in-time
Treasury shares as of March 31, 2023 and December 31, 2022: 106 million ordinary shares	`TreasuryStockValue`	$4.13B	USD	Point-in-time
Stockholders' equity attributable to Teva shareholders	`StockholdersEquity`	$7.86B	USD	Point-in-time
Stockholders' equity attributable to Teva shareholders	`StockholdersEquity`	$7.90B	USD	Point-in-time
Non-controlling interests	`MinorityInterest`	$794.00M	USD	Point-in-time
Non-controlling interests	`MinorityInterest`	$751.00M	USD	Point-in-time
Total equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$8.69B	USD	Point-in-time
Total equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$11.24B	USD	Point-in-time
Total equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$10.26B	USD	Point-in-time
Total equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$8.61B	USD	Point-in-time
Total liabilities and equity	`LiabilitiesAndStockholdersEquity`	$44.01B	USD	Point-in-time
Total liabilities and equity	`LiabilitiesAndStockholdersEquity`	$43.46B	USD	Point-in-time

Income Statement 44 line items

Line Item	Tag	Value	Unit	Period
Net revenues	`RevenueFromContractWithCustomerExcludingAssessedTax`	$3.66B	USD	1 Quarter
Net revenues	`RevenueFromContractWithCustomerExcludingAssessedTax`	$3.66B	USD	1 Quarter
Cost of sales	`CostOfGoodsAndServicesSold`	$2.08B	USD	1 Quarter
Cost of sales	`CostOfGoodsAndServicesSold`	$1.92B	USD	1 Quarter
Gross profit	`GrossProfit`	$1.58B	USD	1 Quarter
Gross profit	`GrossProfit`	$1.74B	USD	1 Quarter
Income loss from equity method investments	`IncomeLossFromEquityMethodInvestments`	$21.00M	USD	1 Quarter
Research and development expenses	`ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost`	$225.00M	USD	1 Quarter
Research and development expenses	`ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost`	$234.00M	USD	1 Quarter
Selling and marketing expenses	`SellingAndMarketingExpense`	$546.00M	USD	1 Quarter
Selling and marketing expenses	`SellingAndMarketingExpense`	$584.00M	USD	1 Quarter
General and administrative expenses	`GeneralAndAdministrativeExpense`	$296.00M	USD	1 Quarter
General and administrative expenses	`GeneralAndAdministrativeExpense`	$296.00M	USD	1 Quarter
Intangible assets impairments	`IntangibleAssetsImpairments`	$149.00M	USD	1 Quarter
Intangible assets impairments	`IntangibleAssetsImpairments`	$178.00M	USD	1 Quarter
Other assets impairments, restructuring and other items	`ImpairmentsRestructuringAndOthers`	$128.00M	USD	1 Quarter
Other assets impairments, restructuring and other items	`ImpairmentsRestructuringAndOthers`	$96.00M	USD	1 Quarter
Legal settlements and loss contingencies	`LegalSettlementsAndLossContingencies`	$1.12B	USD	1 Quarter
Legal settlements and loss contingencies	`LegalSettlementsAndLossContingencies`	$233.00M	USD	1 Quarter
Other income	`OtherOperatingIncomeExpenseNet`	$52.00M	USD	1 Quarter
Other income	`OtherOperatingIncomeExpenseNet`	$2.00M	USD	1 Quarter
Operating income (loss)	`OperatingIncomeLoss`	$-713.00M	USD	1 Quarter
Operating income (loss)	`OperatingIncomeLoss`	$2.00M	USD	1 Quarter
Financial expenses, net	`NonoperatingIncomeExpense`	$-260.00M	USD	1 Quarter
Financial expenses, net	`NonoperatingIncomeExpense`	$-258.00M	USD	1 Quarter
Income (loss) before income taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments`	$-971.00M	USD	1 Quarter
Income (loss) before income taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments`	$-258.00M	USD	1 Quarter
Income taxes (benefit)	`IncomeTaxExpenseBenefit`	$-19.00M	USD	1 Quarter
Income taxes (benefit)	`IncomeTaxExpenseBenefit`	$2.00M	USD	1 Quarter
Share in (profits) losses of associated companies, net	`IncomeLossFromEquityMethodInvestments`	$21.00M	USD	1 Quarter
Net income (loss)	`ProfitLoss`	$-238.00M	USD	1 Quarter
Net income (loss)	`ProfitLoss`	$-952.00M	USD	1 Quarter
Net income (loss) attributable to non-controlling interests	`NetIncomeLossAttributableToNoncontrollingInterest`	$3.00M	USD	1 Quarter
Net income (loss) attributable to non-controlling interests	`NetIncomeLossAttributableToNoncontrollingInterest`	$-33.00M	USD	1 Quarter
Net income (loss) attributable to Teva	`NetIncomeLoss`	$-955.00M	USD	1 Quarter
Net income (loss) attributable to Teva	`NetIncomeLoss`	$-205.00M	USD	1 Quarter
Basic	`EarningsPerShareBasic`	$-0.18	USD	1 Quarter
Basic	`EarningsPerShareBasic`	$-0.86	USD	1 Quarter
Diluted	`EarningsPerShareDiluted`	$-0.86	USD	1 Quarter
Diluted	`EarningsPerShareDiluted`	$-0.18	USD	1 Quarter
Basic	`WeightedAverageNumberOfSharesOutstandingBasic`	1.11B	shares	1 Quarter
Basic	`WeightedAverageNumberOfSharesOutstandingBasic`	1.11B	shares	1 Quarter
Diluted	`WeightedAverageNumberOfDilutedSharesOutstanding`	1.11B	shares	1 Quarter
Diluted	`WeightedAverageNumberOfDilutedSharesOutstanding`	1.11B	shares	1 Quarter

Cash Flow Statement 63 line items

Line Item	Tag	Value	Unit	Period
Net income (loss)	`ProfitLoss`	$-238.00M	USD	1 Quarter
Net income (loss)	`ProfitLoss`	$-952.00M	USD	1 Quarter
Depreciation and amortization	`DepreciationAndAmortization`	$323.00M	USD	1 Quarter
Depreciation and amortization	`DepreciationAndAmortization`	$304.00M	USD	1 Quarter
Impairment of long-lived assets and assets held for sale	`AssetImpairmentCharges`	$165.00M	USD	1 Quarter
Impairment of long-lived assets and assets held for sale	`AssetImpairmentCharges`	$189.00M	USD	1 Quarter
Net change in operating assets and liabilities	`IncreaseDecreaseInOperatingCapital`	$-559.00M	USD	1 Quarter
Net change in operating assets and liabilities	`IncreaseDecreaseInOperatingCapital`	$364.00M	USD	1 Quarter
Deferred income taxes net and uncertain tax positions	`DeferredIncomeTaxesNetAndUncertainTaxPositions`	$-175.00M	USD	1 Quarter
Deferred income taxes net and uncertain tax positions	`DeferredIncomeTaxesNetAndUncertainTaxPositions`	$-106.00M	USD	1 Quarter
Stock-based compensation	`ShareBasedCompensation`	$32.00M	USD	1 Quarter
Stock-based compensation	`ShareBasedCompensation`	$24.00M	USD	1 Quarter
Other items	`OtherOperatingActivitiesCashFlowStatement`	$34.00M	USD	1 Quarter
Other items	`OtherOperatingActivitiesCashFlowStatement`	$30.00M	USD	1 Quarter
Net loss (gain) from investments and from sale of long lived assets	`ProfitFromSaleOfLongLivedAssetsAndInvestment`	$23.00M	USD	1 Quarter
Net loss (gain) from investments and from sale of long lived assets	`ProfitFromSaleOfLongLivedAssetsAndInvestment`	$-4.00M	USD	1 Quarter
Net cash provided by (used in) operating activities	`NetCashProvidedByUsedInOperatingActivities`	$-49.00M	USD	1 Quarter
Net cash provided by (used in) operating activities	`NetCashProvidedByUsedInOperatingActivities`	$-145.00M	USD	1 Quarter
Beneficial interest collected in exchange for securitized trade receivables	`ProceedsFromBeneficialInterestInExchangeForSecuritizedTradeReceivables`	$305.00M	USD	1 Quarter
Beneficial interest collected in exchange for securitized trade receivables	`ProceedsFromBeneficialInterestInExchangeForSecuritizedTradeReceivables`	$323.00M	USD	1 Quarter
Purchases of property, plant and equipment	`PaymentsToAcquirePropertyPlantAndEquipment`	$139.00M	USD	1 Quarter
Purchases of property, plant and equipment	`PaymentsToAcquirePropertyPlantAndEquipment`	$157.00M	USD	1 Quarter
Proceeds from sale of business and long lived assets	`ProceedsFromDivestitureOfBusinesses`	$2.00M	USD	1 Quarter
Proceeds from sale of business and long lived assets	`ProceedsFromDivestitureOfBusinesses`	$25.00M	USD	1 Quarter
Acquisition of businesses, net of cash acquired	`PaymentsToAcquireBusinessesNetOfCashAcquired`	-	USD	1 Quarter
Acquisition of businesses, net of cash acquired	`PaymentsToAcquireBusinessesNetOfCashAcquired`	$7.00M	USD	1 Quarter
Purchases of investments and other assets	`PaymentToAcquireMarketableSecuritiesAndOtherAssets`	$4.00M	USD	1 Quarter
Purchases of investments and other assets	`PaymentToAcquireMarketableSecuritiesAndOtherAssets`	$4.00M	USD	1 Quarter
Other investing activities	`PaymentsForProceedsFromOtherInvestingActivities`	$1.00M	USD	1 Quarter
Other investing activities	`PaymentsForProceedsFromOtherInvestingActivities`	$1.00M	USD	1 Quarter
Net cash provided by (used in) investing activities	`NetCashProvidedByUsedInInvestingActivities`	$181.00M	USD	1 Quarter
Net cash provided by (used in) investing activities	`NetCashProvidedByUsedInInvestingActivities`	$161.00M	USD	1 Quarter
Repayment of senior notes and loans and other long term liabilities	`RepaymentsOfLongTermDebt`	-	USD	1 Quarter
Repayment of senior notes and loans and other long term liabilities	`RepaymentsOfLongTermDebt`	$3.15B	USD	1 Quarter
Proceeds from senior notes, net of issuance costs	`ProceedsFromDebtNetOfIssuanceCosts`	-	USD	1 Quarter
Proceeds from senior notes, net of issuance costs	`ProceedsFromDebtNetOfIssuanceCosts`	$2.45B	USD	1 Quarter
Other financing activities	`ProceedsFromPaymentsForOtherFinancingActivities`	$-5.00M	USD	1 Quarter
Other financing activities	`ProceedsFromPaymentsForOtherFinancingActivities`	$2.00M	USD	1 Quarter
Net cash provided by (used in) financing activities	`NetCashProvidedByUsedInFinancingActivities`	$2.00M	USD	1 Quarter
Net cash provided by (used in) financing activities	`NetCashProvidedByUsedInFinancingActivities`	$-706.00M	USD	1 Quarter
Translation adjustment on cash and cash equivalents	`EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$-62.00M	USD	1 Quarter
Translation adjustment on cash and cash equivalents	`EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$12.00M	USD	1 Quarter
Net change in cash, cash equivalents and restricted cash	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect`	$52.00M	USD	1 Quarter
Net change in cash, cash equivalents and restricted cash	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect`	$-658.00M	USD	1 Quarter
Balance of cash, cash equivalents and restricted cash at beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$2.18B	USD	Point-in-time
Balance of cash, cash equivalents and restricted cash at beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$2.25B	USD	Point-in-time
Balance of cash, cash equivalents and restricted cash at beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$2.20B	USD	Point-in-time
Balance of cash, cash equivalents and restricted cash at beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$2.83B	USD	Point-in-time
Balance of cash, cash equivalents and restricted cash at end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$2.18B	USD	Point-in-time
Balance of cash, cash equivalents and restricted cash at end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$2.25B	USD	Point-in-time
Balance of cash, cash equivalents and restricted cash at end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$2.20B	USD	Point-in-time
Balance of cash, cash equivalents and restricted cash at end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$2.83B	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$2.80B	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$2.14B	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$2.17B	USD	Point-in-time
Restricted cash included in other current assets	`RestrictedCashAndCashEquivalentsAtCarryingValue`	$33.00M	USD	Point-in-time
Restricted cash included in other current assets	`RestrictedCashAndCashEquivalentsAtCarryingValue`	$75.00M	USD	Point-in-time
Total cash, cash equivalents and restricted cash shown in the statement of cash flows	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$2.18B	USD	Point-in-time
Total cash, cash equivalents and restricted cash shown in the statement of cash flows	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$2.25B	USD	Point-in-time
Total cash, cash equivalents and restricted cash shown in the statement of cash flows	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$2.20B	USD	Point-in-time
Total cash, cash equivalents and restricted cash shown in the statement of cash flows	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$2.83B	USD	Point-in-time
Beneficial interest obtained in exchange for securitized accounts receivables	`BeneficialInterestObtainedInExchangeForSecuritizedTradeReceivables`	$299.00M	USD	Point-in-time
Beneficial interest obtained in exchange for securitized accounts receivables	`BeneficialInterestObtainedInExchangeForSecuritizedTradeReceivables`	$334.00M	USD	Point-in-time

Stockholders Equity 15 line items

Line Item	Tag	Value	Unit	Period
Beginning balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$8.69B	USD	Point-in-time
Beginning balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$11.24B	USD	Point-in-time
Beginning balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$10.26B	USD	Point-in-time
Beginning balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$8.61B	USD	Point-in-time
Net income (loss)	`ProfitLoss`	$-238.00M	USD	1 Quarter
Net income (loss)	`ProfitLoss`	$-952.00M	USD	1 Quarter
Other comprehensive income (loss)	`OtherComprehensiveIncomeLossNetOfTax`	$127.00M	USD	1 Quarter
Other comprehensive income (loss)	`OtherComprehensiveIncomeLossNetOfTax`	$-57.00M	USD	1 Quarter
Issuance of Shares, value	`StockIssuedDuringPeriodValueNewIssues`	$1.00M	USD	1 Quarter
Stock-based compensation expense	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$24.00M	USD	1 Quarter
Stock-based compensation expense	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$32.00M	USD	1 Quarter
Ending balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$8.69B	USD	Point-in-time
Ending balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$11.24B	USD	Point-in-time
Ending balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$10.26B	USD	Point-in-time
Ending balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$8.61B	USD	Point-in-time

Comprehensive Income 16 line items

Line Item	Tag	Value	Unit	Period
Net income (loss)	`ProfitLoss`	$-238.00M	USD	1 Quarter
Net income (loss)	`ProfitLoss`	$-952.00M	USD	1 Quarter
Currency translation adjustment	`OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax`	$-64.00M	USD	1 Quarter
Currency translation adjustment	`OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax`	$120.00M	USD	1 Quarter
Unrealized gain (loss) from derivative financial instruments, net	`UnrealizedGainLossOnDerivativeNetOfTax`	$7.00M	USD	1 Quarter
Unrealized gain (loss) from derivative financial instruments, net	`UnrealizedGainLossOnDerivativeNetOfTax`	$8.00M	USD	1 Quarter
Unrealized loss on defined benefit plans	`OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationNetOfTax`	-	USD	1 Quarter
Unrealized loss on defined benefit plans	`OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationNetOfTax`	$-1.00M	USD	1 Quarter
Total other comprehensive income (loss)	`OtherComprehensiveIncomeLossNetOfTax`	$127.00M	USD	1 Quarter
Total other comprehensive income (loss)	`OtherComprehensiveIncomeLossNetOfTax`	$-57.00M	USD	1 Quarter
Total comprehensive income (loss)	`ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest`	$-1.01B	USD	1 Quarter
Total comprehensive income (loss)	`ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest`	$-111.00M	USD	1 Quarter
Comprehensive income (loss) attributable to non-controlling interests	`ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest`	$-50.00M	USD	1 Quarter
Comprehensive income (loss) attributable to non-controlling interests	`ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest`	$-42.00M	USD	1 Quarter
Comprehensive income (loss) attributable to Teva	`ComprehensiveIncomeNetOfTax`	$-959.00M	USD	1 Quarter
Comprehensive income (loss) attributable to Teva	`ComprehensiveIncomeNetOfTax`	$-69.00M	USD	1 Quarter

Data is extracted from SEC EDGAR XBRL filings. Values shown are as reported in the filing.